MARKET

PRAX

PRAX

Praxis Precision Medicines, Inc.
NASDAQ
37.10
-0.22
-0.59%
After Hours: 37.10 0 0.00% 16:33 05/14 EDT
OPEN
37.64
PREV CLOSE
37.32
HIGH
37.96
LOW
35.41
VOLUME
277.33K
TURNOVER
--
52 WEEK HIGH
91.83
52 WEEK LOW
26.70
MARKET CAP
755.69M
P/E (TTM)
-3.4639
1D
5D
1M
3M
1Y
5Y
1D
Piper Sandler Reaffirms Their Buy Rating on Praxis Precision Medicines (PRAX)
TipRanks · 2d ago
Weekly Report: what happened at PRAX last week (0505-0509)?
Weekly Report · 2d ago
Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside
Benzinga · 05/07 19:26
AMD upgraded, Electronic Arts downgraded: Wall Street’s top analyst calls
TipRanks · 05/07 13:41
This Waste Connections Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Benzinga · 05/07 11:51
Praxis Precision Med Price Target Announced at $80.00/Share by Chardan Capital
Dow Jones · 05/07 10:50
Chardan Capital Initiates Coverage On Praxis Precision Medicine with Buy Rating, Announces Price Target of $80
Benzinga · 05/07 10:40
Praxis Precision initiated with a Buy at Chardan
TipRanks · 05/07 08:50
More
About PRAX
More
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The Company is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small-molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The Company’s product candidates include ulixacaltamide, vormatrigine, relutrigine, PRAX-080, and others.
Recently
Symbol
Price
%Change

Webull offers Praxis Precision Medicines Inc stock information, including NASDAQ: PRAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRAX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PRAX stock methods without spending real money on the virtual paper trading platform.